FluoroPharma Medical, developer of advanced medical diagnostic imaging products, with a current focus on imaging agents for breakthrough positron emission tomography (PET) applications, obtains critical advice and guidance from a scientific advisory board made up of top experts in the fields of medical imagery and cardiology.
• Daniel Berman, MD, FACC, is Chief of Cardiac Imaging and Nuclear Cardiology at Cedars-Sinai Heart Center and Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. A world-renowned expert in nuclear cardiology (the use of noninvasive nuclear imaging for the study of cardiovascular disease), he is one of the principal developers of techniques now widely used in nuclear cardiology.
• Peter Conti, MD, PhD, is Professor of Radiology, Biomedical Engineering, and Pharmacy at the University of Southern California, and has been Director of the USC PET Imaging Science Center since its inception in 1991. One of his major areas of research is in the development of molecular imaging agents for the diagnosis and monitoring of cancer metabolism and cell proliferation.
• Elazer Edelman, MD, PhD, is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a coronary care unit cardiologist at the Brigham and Women’s Hospital in Boston. He directs the Harvard-MIT Biomedical Engineering Center (BMEC), investigating ways to elucidate the fundamental biologic processes and mechanisms of disease.
• Heinrich Schelbert, MD, PhD, is Professor of Pharmacology and Radiological Sciences and a Chief of Cardiovascular Nuclear Medicine at the UCLA School of Medicine. He’s made seminal contributions related to cardiac PET imaging, including development of a radiotracer techniques used in non-invasive blood flow imaging, and is Editor-in-Chief of the Journal of Nuclear Medicine.
• Andrew Selwyn, MA, MD, PhD, is Professor of Medicine at Harvard Medical School and a Senior Physician and Associate Chief of the Cardiovascular Division (academic affairs) at Brigham and Women’s Hospital. He is a leading contributor to the research and clinical practice of interventional cardiology and biology of atherosclerosis.
For more information, see the company website at www.FluoroPharma.com
Let us hear your thoughts below: